Leerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on EPIRUS Biopharmaceuticals (NASDAQ: EPRS) to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE